Novan, Inc. (NASDAQ:NOVN) Files An 8-K Regulation FD Disclosure
Item 7.01.
|
Regulation FD Disclosure. |
On March 6, 2017, Novan, Inc. (the Company) issued a press
release providing an update regarding its SB204 development
program. In addition, the Company published an updated corporate
presentation on its website at www.Novan.com. The press release
and the corporate presentation are furnished herewith as Exhibit
99.1 and Exhibit 99.2, respectively, to this Current Report and
are incorporated herein by reference.
In accordance with General Instruction B.2. of Form 8-K, the
information contained in, or incorporated into, this Item 7.01,
including the press release and corporate presentation attached
as Exhibit 99.1 and Exhibit 99.2, respectively, is being
furnished and shall not be deemed filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any
of the Companys filings under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
|
Item 9.01. |
Financial Statements and Exhibits. |
|
(d) |
Exhibits |
See the Exhibit Index which follows the page of this Current
Report on Form 8-K, which is incorporated herein by reference.
About Novan, Inc. (NASDAQ:NOVN)
Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company’s formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate. Novan, Inc. (NASDAQ:NOVN) Recent Trading Information
Novan, Inc. (NASDAQ:NOVN) closed its last trading session up +0.45 at 6.39 with 341,830 shares trading hands.
